Related Experiment Video
Updated: Feb 24, 2026
A Murine Closed-chest Model of Myocardial Ischemia and Reperfusion
Published on: July 17, 2012
Cilostazol protects mice against myocardium ischemic/reperfusion injury by activating a PPARγ/JAK2/STAT3 pathway
Jiangjin Li1, Xiaoli Xiang2, Xiaoxuan Gong1
1Department of Cardiology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, Jiangsu, PR China.
Abstract:
Myocardial ischemia/reperfusion (MIR) injury causes severe arrhythmias and a high lethality. The present study is designed to investigate the effect of cilostazol on MIR injury and the underlying mechaism. We measured the effects of cilostazol on heart function parameters in a mouse model of MIR. Proinflammatory cytokines and apoptosis proteins in the myocardium were examined to investigate the anti-inflammatory and anti-apoptosis ability of cilostazol. The participation of PPARγ/JAK2/STAT3 pathway was investigated. Results showed that the impairment of hemodynamic parameters caused by MIR was attenuated by cilostazol. The IL-6, IL-1β and TNF-a levels were all decreased by cilostazol. Cilostazol also significantly inhibited Bax and cleaved caspase-3 levels and restored the Bcl-2 levels. PPARγ, JAK2 and STAT3 were all activated by cilostazol. Treatment of inhibitors of them abolished the protective effects of cilostazol on cardiac function, myocardial inflammation and apoptosis. In summary, cilostazol alleviated the cardiac function impairment, myocardial inflammation and apoptosis induced by MIR. The results present a novel signaling mechanism that cilostazol protects MIR injury by activating a PPARγ/JAK2/STAT3 pathway.
Insights
Cilostazol protects against myocardial ischemia/reperfusion (MIR) injury by reducing inflammation and apoptosis. This cardioprotective effect is mediated by activating the PPARγ/JAK2/STAT3 pathway, offering a novel therapeutic mechanism for MIR.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Molecular Medicine
Background:
- Myocardial ischemia/reperfusion (MIR) injury leads to severe arrhythmias and high mortality.
- Understanding the molecular mechanisms underlying MIR injury is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the protective effects of cilostazol on MIR injury.
- To elucidate the underlying molecular mechanisms, focusing on the PPARγ/JAK2/STAT3 pathway.
Main Methods:
- A mouse model of MIR was used to assess cardiac function and hemodynamic parameters.
- Levels of proinflammatory cytokines (IL-6, IL-1β, TNF-α) and apoptosis proteins (Bax, Bcl-2, cleaved caspase-3) were measured.
- The involvement of the PPARγ/JAK2/STAT3 pathway was examined using pathway activators and inhibitors.
Main Results:
- Cilostazol significantly improved hemodynamic parameters impaired by MIR.
- Cilostazol reduced myocardial levels of IL-6, IL-1β, and TNF-α, and modulated apoptosis proteins by inhibiting Bax and cleaved caspase-3 while restoring Bcl-2.
- Cilostazol activated the PPARγ/JAK2/STAT3 pathway, and inhibiting this pathway abolished cilostazol's protective effects.
Conclusions:
- Cilostazol alleviates cardiac dysfunction, inflammation, and apoptosis associated with MIR injury.
- The cardioprotective effects of cilostazol are mediated through the activation of the PPARγ/JAK2/STAT3 signaling pathway.
